WNY0824

DB23606ExperimentalSmall molecule

WNY0824 is a preclinical small molecule drug being investigated for the treatment of Castration-Resistant Prostrate Cancer (CRPC). It is a dual inhibitor of PLK-1 and BRET-4, which have both been...

Mechanism: Pharmacologically active on Serine/threonine-protein kinase PLK1 and Bromodomain-containing protein 4
Curator reviewed
Formula / weight: C₃₁H₄₃N₉O₂ · 573.746 g/mol (avg)
Also known as: PLK1/BRD4-IN-1
Code names: GLXC-25328 · GTPL12143 · WNY0824

Resolves to

Compound

CAS2412707-81-2ChEMBLCHEMBL4747491

Structure

InChIKeyQUMCIHKVKQYNPA-RUZDIDTESA-NSMILES[H][C@]1(CC)N(CC2CCCCC2)C2=NC(NC3=C(OC)C=C(C=C3)C(\O)=N\C3CCN(C)CC3)=NC=C2N2C(C)=NN=C12

Targets

P53350PLK1O60885BRD4

What you can answer from here — as of August 31, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with WNY0824, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account